Intratympanic gentamicin for Ménière's disease: Effect on quality of life as assessed by Glasgow benefit inventory

Journal of Laryngology and Otology

Volumn 120, Issue 10, 2006, Pages 827-831

  Banerjee, A S ^a,b   Johnson, I J M ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Gentamicin; Meniere's Disease; Quality of Life

Indexed keywords

GENTAMICIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ELECTRONYSTAGMOGRAPHY; FEMALE; GLASGOW OUTCOME SCALE; HEARING LOSS; HUMAN; LABYRINTHECTOMY; MALE; MENIERE DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY OF LIFE; QUESTIONNAIRE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; FEMALE; GENTAMICINS; HUMANS; INJECTIONS; MALE; MENIERE'S DISEASE; MIDDLE AGED; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TYMPANIC MEMBRANE;

EID: 33750695294     PISSN: 00222151     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0022215106001605     Document Type: Article

References (17)

1. Committee on Hearing and Equilibrium. Guidelines for the diagnosis and evaluation of therapy in Meniere's disease. Otolaryngol Head Neck Surg 1995;113:181-5
2. Gibson WPR, Arenberg IK. Pathophysiologic theories in the etiology of Meniere's disease. Otolaryngol Clin North Amer 1997;30:961-8
3. Masutani H, Takahashi H, Sando I. Dark cell pathology in Meniere's disease. Acta Otolaryngol 1992;112:479-85
4. Kimura RS. Distribution, structure and function of dark cells in the vestibular labyrinth. Ann Otol Rhinol Laryngol 1969;78:542-61
5. Pender DJ. Gentamicin tympanoclysis: effects on the vestibular secretory cells. Am J Otolaryngol 1985;6:358-67
6. Yoshihara T, Kaname H, Ishii T, Igarashi M. Effect of gentamycin on vestibular dark cells and melanocytes: an ultrastructural and cytochemical study. ORL J Otorhinolaryngol Relat Spec 1994;56:24-30
7. Fowler EP. Streptomycin treatment of vertigo. Trans Am Acad Ophthalmol Otolaryngol 1948;52:239-301
8. Shuknecht HF. Ablation therapy in management of Meniere's disease. Acta Otolaryngol 1957;132:3-42
9. Driscoll CL, Kasperbauer JL, Facer GW, Harner SG, Beatty CW. Low-dose intratympanic gentamicin and the treatment of Meniere's disease: preliminary results. Laryngoscope 1997;107:83-9
10. Kinney SE, Sandridge SA, Newman CW. Long-term effects of Meniere's disease on hearing and quality of life. Am J Otol 1997;18:67-73
11. Robinson K, Gatehouse S, Browning GG. Measuring patient benefit from otorhinolaryngological surgery and therapy. Ann Otol Rhinol Laryngol 1996;105:415-22
12. Obholzer RJ, Wareing MJ. Intratympanic gentamicin for Meniere's disease; a survey of current UK practice. J Laryngol Otol 2003;117:459-61
13. Assimakopoulos D, Patrikakos G. Treatment of Meniere's disease by intratympanic gentamicin application. J Laryngol Otol 2003;117:10-16
14. Brian Bakley. Update on intratympanic gentamicin for Meniere's disease. Laryngoscope 2000;110:236-40
15. Soderman AC, Bergenius J, Bagger-Sjoback D, Tjell C, Langius A. Patients' subjective evaluations of quality of life related to disease-specific symptoms, sense of coherence, and treatment in Meniere's disease. Otol Neurotol 2001;22:526-33
16. Soderman AC, Bagger-Sjoback D, Bergenius J, Langius A. Factors influencing quality of life in patients with Meniere's disease, identified by a multidimensional approach. Otol Neurotol 2002;23:941-8
17. Arunachalam PS, Kilby D, Meikle D, Davison T, Johnson IJM. Bone anchored hearing aid - quality of life assessed by Glasgow benefit inventory. Laryngoscope 2001;111: 1260-3